KJ-C2527

KJ-C2527 is a potent and selective small molecule inhibitor designed to disrupt the protein-protein interaction between the MYC oncoprotein and its obligatory partner, MAX. MYC is a transcription factor that is frequently deregulated in a wide array of human cancers, driving cell proliferation, metabolism, and survival. By binding to the MYC-MAX heterodimerization interface, KJ-C2527 prevents the formation of the functional complex required for DNA binding and transcriptional activation of MYC target genes. Developed through research at The Scripps Research Institute, this compound demonstrates the feasibility of targeting transcription factors, which were historically considered "undruggable." Preclinical studies have shown that KJ-C2527 effectively inhibits the proliferation of MYC-overexpressing cancer cells and reduces tumor growth in xenograft models, particularly in MYC-driven malignancies such as Burkitt lymphoma.